UCB’s Vimpat (lacosamide) Receives CHMP’s Positive Opinion for Primary Generalized Tonic-Clonic Seizures

October 23, 2020 Auto Bot receives, regulatory 0

Shots:

  • The EMA’s CHMP has adopted a positive opinion on a license extension for Vimpat (lacosamide) and Lacosamide UCB (lacosamide) as an adjunctive therapy in the treatment for PGTCS in adults, adolescents, and children from 4 years of age with idiopathic generalized epilepsy
  • The CHMP’s positive opinion is based on P-lll study assessing lacosamide as an adjunctive treatment for uncontrolled PGTCS. The therapy lowered the risk of developing a second PGTCS during a 24wks. period and demonstrated a higher rate of freedom from PGTCS during the treatment period
  • The company expects the EC’s formal approval decision before the end of 2020, that broaden the clinical application of Vimpat and make a new treatment option available to aid the management of PGTCS

Click here ­to­ read full press release/ article | Ref: UCB | Image: BioExcel

The post UCB’s Vimpat (lacosamide) Receives CHMP’s Positive Opinion for Primary Generalized Tonic-Clonic Seizures first appeared on PharmaShots.